If FCR is definitely the treatment of option, warning need to be taken in individuals with NOTCH1 mutations, in whom rituximab seems to get little additional benefit.59 Other genomic subgroups, for instance individuals with BIRC3 mutations show up to derive very little gain from CIT,111,112 but these results needs to be more validated.Look for syst